Русский
Prognostication of non-alcoholic fatty liver disease in people of young age
DOI: https://dx.doi.org/10.18565/therapy.2024.2.26-31
Pankova E.D., Chulkov V.S., Ektova N.A.
1) South Ural State Medical University of the Ministry of Healthcare of Russia, Chelyabinsk; 2) Yaroslaw-the-Wise Novgorod State University, Veliky Novgorod
The aim: to develop a model for NAFLD prediction in young adults.
Material and methods. The “case – control” study included 100 patients, divided into two groups: group 1 (“cases”) – individuals with NAFLD (n = 50); group 2 (“controls”) – individuals without NAFLD (n = 50). All of them underwent clinical examination, questionnaires, and laboratory and instrumental research.
Results. Among the cardiometabolic risk factors in NAFLD patients, impaired fasting hyperglycemia, abdominal obesity and hyperuricemia were detected more often than in the control group. Also in group 1 of the study, the highest concentrations of leptin, type 1 plasminogen activator inhibitor and lipoprotein (a) were observed. Body composition in individuals with NAFLD was characterized by a higher content of total and visceral fat. Using logistic regression method, a screening model for assessing the probability of NAFLD presence in young male and female patients was developed. It included 4 parameters: age, gender, visceral fat content and serum lipoprotein (a) concentration. ROC curve was used to build the model. The area under the ROC-curve (AUC) of the model was 0.89 (sensitivity – 0.80, specificity – 0.82).
Conclusion. Obtained prognostic model is aimed at the performing of screening diagnosis of NAFLD in young individuals, including asymptomatic patients, with the aim of timely detection and correction of the disease at early stages.
Literature
1. Zarghamravanbakhsh P., Frenkel M., Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metabolism Open. 2021; 12: 100149. https://doi.org/10.1016/j.metop.2021.100149. PMID: 34870138. PMCID: PMC8626571. 2. Chulkov V., Gavrilova E., Chulkov V. et al. Non-alcoholic fatty liver disease and metabolic syndrome among young adults. Atherosclerosis. 2023; 379(S1): S102–S103. https://doi.org/10.1016/j.atherosclerosis.2023.06.370. 3. Bansal S., Vachher M., Arora T. et al. Visceral fat: A key mediator of NAFLD development and progression. Human Nutrition & Metabolism. 2023; 33: 1–12. https://doi.org/10.1016/j.hnm.2023.200210. 4. Kronenberg F., Mora S., Stroes E.S.G. et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. Eur Heart J. 2022; 43(39): 3925–46. https://doi.org/10.1093/eurheartj/ehac361. PMID: 36036785. PMCID: PMC9639807. 5. Чулков Вл.С., Сумеркина В.А., Абрамовских О.С. с соавт. Частота неалкогольной жировой болезни печени у молодых пациентов с абдоминальным ожирением на фоне артериальной гипертензии. Экспериментальная и клиническая гастроэнтерология. 2014; (11): 42–45. (Chulkov Vl.S., Sumerkina V.A, Abramovskikh O.S. et al. Frequency of non-alcoholic fatty liver disease in young patients with abdominal obesity on the background of hypertension. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2014; (11): 42–45 (In Russ.)). EDN: SZUVRD. 6. Лазебник Л.Б. Steatotic liver disease – стеатозная болезнь печени – международная трактовка понятия «зонтика» для всех заболеваний печеночной паренхимы. Экспериментальная и клиническая гастроэнтерология. 2023; (8): 24–26. (Lazebnik L.B. Steatotic liver disease – steatous liver disease is an international interpretation of the concept of an “umbrella” for all diseases of the hepatic parenchyma. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2023; (8): 24–26 (In Russ.)). https://doi.org/10.31146/1682-8658-ecg-216-8-24-26. EDN: JUFFXA. 7. Логачева И.В., Рязанова Т. А., Пономарев С.Б., Макарова В.Р. Многофакторный прогноз развития неалкогольной жировой болезни печени при висцеральном ожирении у больных ишемической болезнью сердца и артериальной гипертензией. Российский кардиологический журнал. 2021; 26(1): 87–92. (Logacheva I.V., Ryazanova T.A., Ponomarev S.B., Makarova V.R. Multifactorial prognosis of nonalcoholic fatty liver disease in visceral obesity in patients with coronary heart disease and hypertension. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021; 26(1): 87–92 (In Russ.)). https://doi.org/10.15829/1560-4071-2021-4015. EDN: AGZQLE. 8. Langsted A., Nordestgaard B.G., Kamstrup P.R. Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study. Eur Heart J. 2021; 42(12): 1147–56. https://doi.org/10.1093/eurheartj/ehaa1085. PMID: 33724357. 9. Zewinger S., Kleber M.E., Tragante V. et al. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: A molecular and genetic association study. Lancet Diabetes Endocrinol. 2017; 5(7): 534–43. https://doi.org/10.1016/S2213-8587(17)30096-7. PMID: 28566218. PMCID: PMC5651679. 10. Gudbjartsson D.F., Thorgeirsson G., Sulem P. et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019; 74(24): 2982–94. https://doi.org/10.1016/j.jacc.2019.10.019. PMID: 31865966. 11. Meroni M., Longo M., Lombardi R. et al. Low lipoprotein(a) levels predict hepatic fibrosis in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2022; 6(3): 535–49. https://doi.org/10.1002/hep4.1830. PMID: 34677008. PMCID: PMC8870034.
About the Autors
Ekaterina D. Pankova, MD, postgraduate student of the Department of faculty therapy, South Ural State Medical University of the Ministry of Healthcare of Russia. Address: 454092, Chelyabinsk, 64 Vorovskogo St.
E-mail: katerinachelsma@yandex.ru
ORCID: https://orcid.org/0000-0002-6301-7630
Vasily S. Chulkov, MD, Dr. Sci. (Medicine), professor of the Department of internal diseases, Yaroslaw-the-Wise Novgorod State University. Address: 173003, Veliky Novgorod, 41 Bolshaya St.Petersburgskaya St.
E-mail: vschulkov@rambler.ru
ORCID: https://orcid.org/0000-0002-0952-6856
Natalya A. Ektova, MD, PhD (Medicine), associate professor of the Department of faculty therapy, South Ural State Medical University of the Ministry of Healthcare of Russia. Address: 454092, Chelyabinsk, 64 Vorovskogo St.
E-mail: Ektnachel@mail.ru
ORCID: https://orcid.org/0000-0002-4416-0853
Similar Articles
